Modulation of the Urea Cycle through the Combined Use of SGLT2 Inhibitors and Metformin - Quiz - MDSpire

Modulation of the Urea Cycle through the Combined Use of SGLT2 Inhibitors and Metformin

  • By

  • Makoto Harada

  • Jonathan Adam

  • Siyu Han

  • Mengya Shi

  • Jianhong Ge

  • Jutta Lintelmann

  • Alexander Cecil

  • Sven Zukunft

  • Cornelia Prehn

  • Michael Witting

  • Markus F. Scheerer

  • Susanne Neschen

  • Martin Irmler

  • Johannes Beckers

  • Jerzy Adamski

  • Daniel Teupser

  • Birgit Linkohr

  • Christian Gieger

  • Martin Hrabě de Angelis

  • Annette Peters

  • Rui Wang-Sattler

  • January 8, 2026

  • 0 min

Share

Original Source(s)

Modulation of the Urea Cycle through the Combined Use of SGLT2 Inhibitors and Metformin

  • by Makoto Harada, Jonathan Adam, Siyu Han, Mengya Shi, Jianhong Ge, Jutta Lintelmann, Alexander Cecil, Sven Zukunft, Cornelia Prehn, Michael Witting, Markus F. Scheerer, Susanne Neschen, Martin Irmler, Johannes Beckers, Jerzy Adamski, Daniel Teupser, Birgit Linkohr, Christian Gieger, Martin Hrabě de Angelis, Annette Peters, Rui Wang-Sattler

  • January 8, 2026

Related Content

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models